Keyphrases
Graft-versus-host Disease (GvHD)
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
71%
Hematopoietic Cell Transplantation
50%
Bone Marrow Transplantation
43%
Unrelated Donor
43%
Acute Myeloid Leukemia
40%
Marrow Transplantation
40%
Confidence Interval
38%
Transplantation
33%
Overall Survival
24%
Allogeneic Bone Marrow Transplantation
23%
Reduced-intensity Conditioning
23%
Acute Lymphoblastic Leukemia
20%
Umbilical Cord Blood
18%
Survivors
16%
Bone Marrow
15%
Hematopoietic Stem Cell Transplantation
15%
Marrow
14%
Umbilical Cord Blood Transplantation
14%
Non-relapse Mortality
14%
Hazard Ratio
14%
Myelodysplastic Syndrome
13%
Chronic Myeloid Leukemia
13%
First Complete Remission
13%
Acute Leukemia
13%
Natural Killer Cells
13%
Unrelated Donor Transplantation
12%
Allogeneic Transplantation
12%
Pretransplant
12%
Relative Risk
11%
Myeloablative
11%
Leukemia Patients
11%
Myeloablative Conditioning
11%
Total Body Irradiation
11%
Transplant Outcomes
11%
High Risk
11%
Risk Factors
11%
Cyclophosphamide
11%
Disease-free Survival
10%
Chemotherapy
10%
Leukemia
9%
Allogeneic
9%
Hematological Malignancies
9%
Reduced Intensity
8%
Peripheral Blood
8%
Worldwide Network
8%
Treatment-related Mortality
8%
HLA Matching
8%
Hematopoietic Cell Transplant
8%
Engraftment
8%
Medicine and Dentistry
Hematopoietic Cell
75%
Cell Transplantation
67%
Bone Marrow Transplantation
41%
Acute Myeloid Leukemia
36%
Graft Versus Host Reaction
33%
Overall Survival
24%
Chronic Graft Versus Host Disease
24%
Diseases
23%
Acute Lymphoblastic Leukemia
22%
Cord Blood
20%
Acute Graft Versus Host Disease
20%
Allograft
18%
Myelodysplastic Syndrome
15%
Reduced Intensity Conditioning
15%
Leukemia
14%
Hazard Ratio
14%
Hematopoietic Stem Cell Transplantation
13%
Conditioning
11%
Chronic Myelogenous Leukemia
11%
Acute Leukemia
11%
Allogenic Bone Marrow Transplantation
11%
Allogeneic Hematopoietic Stem Cell Transplantation
10%
Whole Body Radiation
10%
Infection
10%
Cyclophosphamide
10%
Clinical Trial
9%
Disease Free Survival
9%
Multiple Myeloma
7%
Cord Blood Stem Cell Transplantation
7%
Cumulative Incidence
6%
T Cell
6%
Myeloablative Conditioning
6%
Engraftment
6%
Natural Killer Cell
6%
Drug Megadose
6%
Multivariate Analysis
6%
Hematologic Malignancy
5%
Peripheral Blood Stem Cell
5%
Autotransplantation
5%
Non-Hodgkin Lymphoma
5%
Pediatrics
5%
Immunology and Microbiology
Hematopoietic Cell
73%
Cell Transplantation
69%
Graft-Versus-Host Disease
51%
Acute Graft Versus Host Disease
36%
Conditioning
34%
Bone Marrow Transplantation
32%
Chronic Graft Versus Host Disease
31%
Umbilical Cord Blood
27%
Myeloid
23%
Overall Survival
21%
Allograft
16%
Hematopoietic Stem Cell Transplantation
15%
Cyclophosphamide
14%
Natural Killer Cell
14%
Cord Blood Stem Cell Transplantation
13%
Engraftment
12%
Disease Free Survival
10%
Allogeneic Bone Marrow Transplantation
10%
T Cell
9%
Peripheral Blood Stem Cell
8%
Neutrophil
7%
Allogeneic Hematopoietic Stem Cell Transplantation
7%
Interleukin 2
6%
Cytomegalovirus
6%
Anti-Thymocyte Globulin
6%
Killer-Cell Immunoglobulin-Like Receptor
6%
Drug Megadose
6%
Recurrence Free Survival
5%
Mycophenolate Mofetil
5%
Human Leukocyte Antigen
5%
Multiple Myeloma
5%
Stem Cell
5%